male lower urinary tract symptoms, mLUTS
Conditions
Interventions
Silodosin 8 mg dairy
Tamsulosis 0.2 mg dairy
Sponsors
Department of Urology, The University of Tokyo Hospital
Kamijyo Clinic, Meirikai Chuo General Hospital, Tokyo Metropolitan Geriatric Hospital and Institute of Gerontology, Tokyo Kyosai Hospital, Toshiba Hospital, etc.
Eligibility
Sex/Gender
Male
Inclusion criteria
Inclusion criteria: Male patients with newly diagnosed LUTS according to the treatment algorithm of the Clinical Practice Guidelines for Male Lower Urinary Tract Symptoms
Exclusion criteria
Exclusion criteria: Patients who meet any of the following criteria are excluded: 1) Patients taking anticholinergic agents, antidepressants, or antianxiety agents 2) Patients with a history of urinary retention, urinary tract infections, macroscopic haematuria, lower urinary tract surgery, radiotherapy for the pelvic organs, or neurologic disease 3) Patients with pyuria, renal impairment, calculus bladder, or who are urine cytology positive 4) Patients with elevated PSA levels (4.0 ng/mL or over) 5) Patients whose 9th CLSS score is 2 or higher 6) Patients who are not willing to receive drug treatment 7) Patients who cannot answer the questionnaire by themselves 8) Patients classified as ineligible by the investigator
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Results of treatment with silodosin or tamsulosin hydrochloride evaluated by variations in the new CLSS evaluation index (total score and category-specific score). | — |
Secondary
| Measure | Time frame |
|---|---|
| I-PSS, OABSS, Uroflowmetry, Residual urine volume, Prostate volume | — |
Countries
Japan
Contacts
Public ContactMotofumi Suzuki
The University of Tokyo Hospital Department of Urology
Outcome results
None listed